Growth Metrics

Pfizer (PFE) Net Cash Flow (2016 - 2026)

Pfizer has reported Net Cash Flow over the past 18 years, most recently at $544.0 million for Q1 2026.

  • Quarterly Net Cash Flow rose 42.41% to $544.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $211.0 million through Mar 2026, up 121.4% year-over-year, with the annual reading at $49.0 million for FY2025, 102.81% up from the prior year.
  • Net Cash Flow was $544.0 million for Q1 2026 at Pfizer, up from -$202.0 million in the prior quarter.
  • Over five years, Net Cash Flow peaked at $1.8 billion in Q2 2023 and troughed at -$2.1 billion in Q1 2024.
  • The 5-year median for Net Cash Flow is $173.0 million (2025), against an average of -$66.4 million.
  • Year-over-year, Net Cash Flow skyrocketed 3412.5% in 2022 and then plummeted 405.84% in 2024.
  • A 5-year view of Net Cash Flow shows it stood at -$507.0 million in 2022, then surged by 38.07% to -$314.0 million in 2023, then plummeted by 450.32% to -$1.7 billion in 2024, then skyrocketed by 88.31% to -$202.0 million in 2025, then soared by 369.31% to $544.0 million in 2026.
  • Per Business Quant, the three most recent readings for PFE's Net Cash Flow are $544.0 million (Q1 2026), -$202.0 million (Q4 2025), and -$304.0 million (Q3 2025).